Literature DB >> 20386926

Severe Alport syndrome in a young woman caused by a t(X;1)(q22.3;p36.32) balanced translocation.

Kazumoto Iijima1, Kandai Nozu, Koichi Kamei, Makiko Nakayama, Shuichi Ito, Kentaro Matsuoka, Tsutomu Ogata, Hiroshi Kaito, Koichi Nakanishi, Masafumi Matsuo.   

Abstract

The course of renal involvement and hearing loss is much milder in most female X-linked Alport syndromes than in male patients. We examined the molecular mechanism of development of the disease in a female patient with severe Alport syndrome. The patient showed heavy proteinuria, hematuria, neurosensory hearing loss and primary amenorrhea. Renal biopsy findings of electron microscopy and immunostaining of the alpha5 chain of type IV collagen indicated a female X-linked Alport syndrome. G-banding chromosomal analysis showed a t(X;1)(q22.3;p36.32) balanced translocation. Analysis of the collagen type IV (COL4A5) gene by genomic DNA sequencing, complementary DNA (cDNA) sequencing and multiplex ligation-dependent probe amplification assay showed no mutations or deletions/duplications of the gene. However, fluorescence in situ hybridization using the probes for exon 1 and exon 51 of the COL4A5 gene showed disruption of one copy of the gene. Replication R-banding chromosomal analysis indicated preferential inactivation of the normal X chromosome. This is the first report of severe Alport syndrome in a female patient carrying a balanced translocation between the chromosome X and 1 producing the disruption of one copy of COL4A5 gene and silencing of the other copy because of preferential inactivation of the normal X chromosome. Chromosomal abnormalities should be considered in female patients with severe forms of Alport syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20386926     DOI: 10.1007/s00467-010-1514-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  21 in total

Review 1.  The critical region on the human Xq.

Authors:  E Therman; R Laxova; B Susman
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

2.  Different patterns of X inactivation in MZ twins discordant for red-green color-vision deficiency.

Authors:  A L Jørgensen; J Philip; W H Raskind; M Matsushita; B Christensen; V Dreyer; A G Motulsky
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

Review 3.  Functional disomies of the X chromosome influence the cell selection and hence the X inactivation pattern in females with balanced X-autosome translocations: a review of 122 cases.

Authors:  M Schmidt; D Du Sart
Journal:  Am J Med Genet       Date:  1992-01-15

4.  Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.

Authors:  D G Gilliland; K L Blanchard; J Levy; S Perrin; H F Bunn
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

5.  An assay for X inactivation based on differential methylation at the fragile X locus, FMR1.

Authors:  L Carrel; H F Willard
Journal:  Am J Med Genet       Date:  1996-07-12

6.  Alport's syndrome. Emphasizing electron microscopic studies of the glomerulus.

Authors:  G S Spear; R J Slusser
Journal:  Am J Pathol       Date:  1972-11       Impact factor: 4.307

7.  Pathologic characteristics of hereditary nephritis.

Authors:  J Churg; R L Sherman
Journal:  Arch Pathol       Date:  1973-06

8.  Characteristic ultrastructural lesion of the glomerular basement membrane in progressive hereditary nephritis (Alport's syndrome).

Authors:  N Hinglais; J P Grünfeld; E Bois
Journal:  Lab Invest       Date:  1972-11       Impact factor: 5.662

Review 9.  X-chromosome inactivation: molecular mechanisms and genetic consequences.

Authors:  B R Migeon
Journal:  Trends Genet       Date:  1994-07       Impact factor: 11.639

Review 10.  X inactivation, female mosaicism, and sex differences in renal diseases.

Authors:  Barbara R Migeon
Journal:  J Am Soc Nephrol       Date:  2008-04-30       Impact factor: 10.121

View more
  7 in total

1.  Female X-linked Alport syndrome with somatic mosaicism.

Authors:  Kana Yokota; Kandai Nozu; Shogo Minamikawa; Tomohiko Yamamura; Keita Nakanishi; Hisashi Kaneda; Riku Hamada; Yoshimi Nozu; Akemi Shono; Takeshi Ninchoji; Naoya Morisada; Shingo Ishimori; Junya Fujimura; Tomoko Horinouchi; Hiroshi Kaito; Koichi Nakanishi; Ichiro Morioka; Mariko Taniguchi-Ikeda; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2016-10-31       Impact factor: 2.801

Review 2.  Women and Alport syndrome.

Authors:  Michelle N Rheault
Journal:  Pediatr Nephrol       Date:  2011-03-05       Impact factor: 3.714

3.  X-Linked Alport Syndrome in Women: Genotype and Clinical Course in 24 Cases.

Authors:  Antonio Mastrangelo; Marisa Giani; Elena Groppali; Pierangela Castorina; Giulia Soldà; Michela Robusto; Chiara Fallerini; Mirella Bruttini; Alessandra Renieri; Giovanni Montini
Journal:  Front Med (Lausanne)       Date:  2020-11-23

4.  A novel splice site mutation in the COL4A5 gene in a Chinese female patient with rare ocular abnormalities.

Authors:  Chan Zhao; Fang Wang; Yanqin Zhang; Yubing Wen; Ying Su; Chengfen Zhang; Ruifang Sui; Fei Xu; Jie Ding; Fangtian Dong
Journal:  Mol Vis       Date:  2012-08-08       Impact factor: 2.367

5.  Alport Syndrome: De Novo Mutation in the COL4A5 Gene Converting Glycine 1205 to Valine.

Authors:  Pilar Antón-Martín; Cristina Aparicio López; Soraya Ramiro-León; Sonia Santillán Garzón; Fernando Santos-Simarro; Belén Gil-Fournier
Journal:  Clin Med Insights Pediatr       Date:  2012-06-28

Review 6.  Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome.

Authors:  Kandai Nozu; Yutaka Takaoka; Hirofumi Kai; Minoru Takasato; Kensuke Yabuuchi; Tomohiko Yamamura; Tomoko Horinouchi; Nana Sakakibara; Takeshi Ninchoji; China Nagano; Kazumoto Iijima
Journal:  Kidney Res Clin Pract       Date:  2020-12-31

7.  The variable course of women with X-linked Alport Syndrome.

Authors:  Priya Raju; David Cimbaluk; Stephen M Korbet
Journal:  Clin Kidney J       Date:  2013-08-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.